Adicet Bio (NASDAQ:ACET) Azioni

Adicet Bio

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio Inc

<h3>Gainers</h3>
<ul>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares rose 53.5% to $3.0 during Thursday's after-market session. The company's market cap stands at $93.5 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares increased by 17.85% to $10.43. The market value of their outstanding shares is at $65.8 million. </li>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) shares moved upwards by 10.23% to $0.58. The company's market cap stands at $47.9 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock moved upwards by 9.02% to $0.11. The company's market cap stands at $1.3 million. </li>
<li>Ernexa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares moved upwards by 7.51% to $0.2. The market value of their outstanding shares is at $10.3 million. </li>
<li>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) shares rose 7.44% to $0.2. The company's market cap stands at $35.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares decreased by 13.5% to $1.54 during Thursday's after-market session. The market value of their outstanding shares is at $23.8 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares declined by 9.96% to $1.9. The company's market cap stands at $26.1 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) shares decreased by 6.97% to $0.8. The company's market cap stands at $60.6 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares decreased by 6.03% to $0.39. The market value of their outstanding shares is at $9.8 million. </li>
<li>Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) shares decreased by 5.69% to $66.0. The market value of their outstanding shares is at $2.8 billion. </li>
<li>Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) stock decreased by 5.59% to $0.75. The market value of their outstanding shares is at $9.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACET

ADGM

CLSD

ERNA

FORA

HOTH

SLNO

SNSE

SXTC

SYRA

XCUR

XFOR

12 Health Care Stocks Moving In Thursday's After-Market Session

Guggenheim analyst Yatin Suneja reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and maintains $7 price target.

News

Price Target

Reiteration

Analyst Ratings

Guggenheim Reiterates Buy on Adicet Bio, Maintains $7 Price Target

Citizens Capital Markets analyst Reni Benjamin reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Market Perform to Market Perform.

Citizens Capital Markets Reiterates Market Perform on Adicet Bioto Market Perform

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Neutral to Neutral.

HC Wainwright & Co. Reiterates Neutral on Adicet Bioto Neutral

Adicet Bio Reports Poster Presentations Highlighting ADI-270 Data At SITC 2025 Spring Scientific Meeting

Biotech

Health Care

General

The FDA Has Granted Fast Track Designation To Adicet Bio's ADI-001 For The Potential Treatment Of Adult Patients With Systemic Sclerosis

JMP Securities analyst Reni Benjamin reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Market Perform to Market Perform.

JMP Securities Reiterates Market Perform on Adicet Bioto Market Perform

WIIM

Adicet Bio shares are trading higher after the company was granted FDA Fast Track designation to ADI-001 for treating refractory systemic lupus erythematosus with extrarenal involvement.

Adicet Bio Secures FDA Fast Track Status For ADI-001 In Treating Refractory Systemic Lupus Erythematosus (SLE) With Extrarenal Involvement

Adicet Bio Says FDA Granted Fast Track Designation To ADI-001 For Potential Treatment Of Adult Patients With Refractory Systemic Lupus Erythematosus With Extrarenal Involvement

Plans To Advance Phase 1 Trial Of ADI-001 Across Six Autoimmune Diseases With Preliminary Lupus Nephritis Data Expected In 1H25 And Additional Cohort Data In 2H25; Enrollment For SLE, SSc, IIM, And SPS To Begin In Q1 2025, AAV Enrollment Expected In 2H25; Reports First Patient Dosed In ADI-270 Phase 1 Trial For Metastatic ccRCC With Preliminary Data Anticipated In 1H25; Company Positioned To Build On Momentum In Autoimmune And On

Adicet Bio Highlights Key 2025 Milestones Following 2024 Progress

Adicet Bio Says First Patient Dosed In The Phase 1 Clinical Trial Evaluating ADI-270 In Patients With Metastatic/Advanced ccRCC

First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials
Preliminary Phase 1 clinical data expected in the first half of 2025
Adicet Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).

Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical Data Expected In The First Half Of 2025

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Neutral.

HC Wainwright & Co. Reiterates Neutral on Adicet Bio

-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue
-Results highlight the potential benefits unique to gamma delta 1 CAR T cell therapy and ADI-001's potential as a best-in-class off-the-shelf cell therapy for autoimmune diseases
-The company is pursuing ADI-001 in a basket study across six indications including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV)

Reported Saturday, Adicet Bio Shared Clinical Biomarker Data On Off-The-Shelf CAR T Cell Therapy During Oral Session At ACR Convergence 2024

Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 52.11 percent increase over losses of $(0.71) per share from the same period last year.

Earnings

Earnings Beats

Adicet Bio Q3 EPS $(0.34) Beats $(0.35) Estimate

Press Releases

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Comments

Adicet Bio

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO